Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic cell transplantation (HCT) is associated with systemic inflammation and endothelial dysfunction, increasing risk for thromboembolic events (TEE). In 145 adult recipients who developed cGVHD after a matched sibling or umbilical cord blood donor HCT from 2010 to 2018, 32(22%) developed at least 1 TEE event, and 14(10%) developed 2 TEE events. The 5-year cumulative incidence of TEE was 22% (95% CI, 15–29%) with a median time from cGVHD to TEE of 234 days (range, 12–2050). Median time to the development of LE DVT or PE was 107 (range, 12–1925) compared to 450 days (range, 158–1300) for UE DVT. Cumulative incidence of TEE was 9% (95% CI, 0–20%), 17% (95% CI, 9–25%), and 38% (95% CI, 22–55%) in those with mild, moderate, and severe GVHD, respectively. Higher risk for TEE was associated with cGVHD severity (hazard ratio [HR] 4.9, [95% CI, 1.1–22.0]; p = 0.03), non-O-donor to recipient ABO match compared to O-donor to O-recipient match (HR 2.7, [95% CI, 1.0–7.5]; p = 0.053), and personal history of coronary artery disease (HR 2.4, [95% CI, 1.1–5.3]; p = 0.03). TEE was not associated with 2-year non-relapse mortality or 5-year overall survival.

异基因造血细胞移植 (HCT) 后的慢性移植物抗宿主病 (cGVHD) 与全身炎症和内皮功能障碍相关，从而增加血栓栓塞事件 (TEE) 的风险。从 2010 年到 2018 年，在匹配的兄弟姐妹或脐带血供者 HCT 后发生 cGVHD 的 145 名成年受者中，32 人（22%）发生了至少 1 次 TEE 事件，14 人（10%）发生了 2 次 TEE 事件。TEE 的 5 年累积发病率为 22%（95% CI，15-29%），从 cGVHD 到 TEE 的中位时间为 234 天（范围，12-2050）。LE DVT 或 PE 发展的中位时间为 107 天（范围，12-1925），而 UE DVT 为 450 天（范围，158-1300）。轻度、中度 TEE 的累积发生率为 9%（95% CI，0-20%）、17%（95% CI，9-25%）和 38%（95% CI，22-55%） ，和严重的GVHD，分别。p  = 0.03）、非 O 供体与受者 ABO 匹配与 O 供体与 O 受者匹配相比（HR 2.7，[95% CI，1.0-7.5]；p  = 0.053），以及冠状动脉疾病的个人病史（HR 2.4，[95% CI，1.1–5.3]；p  = 0.03）。TEE 与 2 年非复发死亡率或 5 年总生存率无关。